C

    Charles River Laboratories (CRL)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE

    $288.27
    -3.22 (-1.11%)

    Market Cap: $13.76B

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    100%(40/40)
    Avg Surprise
    +9.33%
    Streak
    44 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$2.95
    Range$2.92 - $3.00
    11 analysts
    EPS Revisions
    1
    0
    7d
    1
    7
    30d
    EPS Estimate Drift
    90d ago$3.04+3.1%
    60d ago$3.04+3.1%
    30d ago$3.05+3.2%
    7d ago$2.95-0.1%
    Current$2.95
    Revenue Consensus
    $959M
    Range$952M - $984M
    9 analysts
    Period ending Dec 31, 2026
    EPS Consensus$3.69
    Range$3.40 - $3.83
    16 analysts
    Revenue Consensus
    $997M
    Range$985M - $1.0B
    12 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$3.69---
    Sep 26EST
    		-$2.95---
    Jun 26
    Reported Aug 5
    		$3.02$2.72+11.03%Beat-3.2%
    Mar 26
    Reported May 7
    		$2.06$1.95+5.64%Beat-12.0%
    Dec 25
    Reported Feb 18
    		$2.39$2.33+2.58%Beat-10.2%
    Sep 25
    Reported Nov 5
    		$2.43$2.32+4.74%Beat-6.2%
    Jun 25
    Reported Aug 6
    		$3.12$2.55+22.35%Beat+11.4%
    Mar 25
    Reported May 7
    		$2.34$2.07+13.04%Beat+3.1%
    Dec 24
    Reported Feb 19
    		$2.66$2.53+5.14%Beat+8.1%
    Sep 24
    Reported Nov 6
    		$2.59$2.42+7.02%Beat-4.8%
    Jun 24
    Reported Aug 7
    		$2.80$2.39+17.15%Beat+4.1%
    Mar 24
    Reported May 9
    		$2.27$2.06+10.19%Beat-18.3%
    Dec 23
    Reported Feb 14
    		$2.46$2.40+2.50%Beat-17.4%
    Sep 23
    Reported Nov 8
    		$2.72$2.37+14.77%Beat+3.4%
    Jun 23
    Reported Aug 9
    		$2.69$2.64+1.89%Beat-2.9%
    Mar 23
    Reported May 11
    		$2.78$2.59+7.34%Beat+1.1%
    Dec 22
    Reported Feb 22
    		$2.98$2.75+8.36%Beat+19.7%
    Sep 22
    Reported Nov 2
    		$2.63$2.50+5.20%Beat-2.6%
    Jun 22
    Reported Aug 3
    		$2.77$2.74+1.09%Beat+6.1%
    Mar 22
    Reported May 4
    		$2.75$2.72+1.10%Beat+8.7%
    Dec 21
    Reported Feb 16
    		$2.49$2.43+2.47%Beat+4.2%
    Sep 21
    Reported Nov 3
    		$2.70$2.58+4.65%Beat+15.9%
    Jun 21
    Reported Aug 4
    		$2.61$2.38+9.66%Beat+65.2%
    Mar 21
    Reported May 4
    		$2.53$2.19+15.53%Beat+37.5%
    Dec 20
    Reported Feb 17
    		$2.39$2.11+13.27%Beat+18.9%
    Sep 20
    Reported Oct 29
    		$2.33$1.80+29.44%Beat+37.9%
    Jun 20
    Reported Aug 5
    		$1.58$1.28+23.44%Beat-3.1%
    Mar 20
    Reported May 7
    		$1.84$1.46+26.03%Beat+31.4%
    Dec 19
    Reported Feb 11
    		$2.01$1.83+9.84%Beat+34.9%
    Sep 19
    Reported Nov 6
    		$1.69$1.64+3.05%Beat+10.5%
    Jun 19
    Reported Jul 31
    		$1.63$1.55+5.16%Beat+0.6%
    Mar 19
    Reported May 7
    		$1.40$1.39+0.72%Beat+1.4%
    Dec 18
    Reported Feb 13
    		$1.49$1.40+6.43%Beat+6.4%
    Sep 18
    Reported Nov 7
    		$1.53$1.38+10.87%Beat+17.7%
    Jun 18
    Reported Aug 8
    		$1.62$1.46+10.96%Beat+25.6%
    Mar 18
    Reported May 10
    		$1.38$1.26+9.52%Beat+7.0%
    Dec 17
    Reported Feb 13
    		$1.40$1.25+12.00%Beat+15.7%
    Sep 17
    Reported Nov 9
    		$1.30$1.22+6.56%Beat+10.2%
    Jun 17
    Reported Aug 9
    		$1.29$1.22+5.74%Beat-
    Mar 17
    Reported May 10
    		$1.29$1.14+13.16%Beat-
    Dec 16
    Reported Feb 14
    		$1.21$1.11+9.01%Beat-
    Sep 16
    Reported Nov 2
    		$1.18$1.13+4.42%Beat-

    Key Metrics

    Valuation
    P/E Ratio29.12EV/EBITDA77.04x
    Price/FCF37.35xFCF Yield2.68%
    Profitability
    Profit Margin-5.96%Operating Margin15.10%
    ROE-7.52%ROIC0.05%
    Financial Health
    Debt/Equity0.92xInterest Coverage0.02x
    Current Ratio1.35xQuick Ratio1.04x
    Trading Statistics
    Beta1.38Avg Volume984.58K
    52-Week High$303.3152-Week Low$144.26

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$292.33
    SMA 20$282.13
    SMA 50$247.17
    SMA 200$197.73
    EMA 10$289.96
    EMA 20$279.71
    EMA 50$251.73
    EMA 200$204.71

    MACD

    Line: 14.97Signal: 16.54Hist: -1.57

    ADX

    ADX: 49.0+DI: 27.9-DI: 16.3

    Aroon & PSAR

    Aroon Up92.0
    Aroon DownN/A
    PSAR$303.03

    Bollinger Bands

    Upper Band$313.41
    Lower Band$250.85
    %B Position2217%(Upper)
    Band Width0.60

    RSI (14-Day)

    Neutral
    64.4

    Momentum Oscillators

    Stoch %K62.6
    Stoch %D75.5
    Williams %R-56.4
    ROC (10d)0.6%
    Momentum1.64
    CCI (20d)37.6
    MFI (14d)58.2

    Volatility Measures

    ATR (14d)$9.63(3.3%)
    StdDev (20d)15.64
    Hist Vol46.3%(High)

    Volume Flow

    VWAP$288.01
    OBV18.3M
    AD Line33.7M
    CMF (20d)0.198

    Volume Metrics

    Avg Vol (20d)1.0M
    Vol Ratio1.1x
    VWMA (20d)$280.64

    Pivot Points

    R3$299.68
    R2$297.28
    R1$294.39
    Pivot Point$291.99
    S1$289.10
    S2$286.71
    S3$283.82

    Advanced Oscillators

    TSI45.42
    Ultimate Osc53.2
    KST234.32

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.00B$995.83M$994.23M$1.00B$1.03B$984.17M$1.00B$1.01B$1.03B$1.01B$1.01B$1.03B
    Cost of Revenue$640.70M$701.17M$684.54M$666.06M$675.07M$666.44M$718.30M$660.74M$672.40M$666.72M$649.39M$664.78M
    Gross Profit$363.37M$294.66M$309.68M$338.79M$357.07M$317.73M$284.24M$349.02M$353.71M$344.84M$364.08M$361.84M
    Operating Expenses$243.49M$174.77M$593.12M$204.99M$256.93M$243.06M$451.93M$231.62M$202.06M$218.87M$231.16M$210.34M
    R&D$0$0$0$0$0$0$0$0$0$0$0$0
    SG&A$228.90M$159.42M$196.14M$177.59M$191.55M$177.80M$195.71M$199.21M$169.79M$186.29M$197.14M$176.11M
    Operating Income$119.89M$119.90M$-283,440,000$133.80M$100.13M$74.67M$-167,687,000$117.41M$151.65M$125.98M$132.92M$151.50M
    Interest Income$1.03M$1.03M$1.02M$1.42M$1.10M$1.40M$1.83M$1.53M$3.01M$2.20M$1.59M$1.37M
    Interest Expense$30.34M$26.74M$23.77M$25.40M$29.97M$27.88M$28.23M$30.28M$32.77M$35.00M$33.54M$33.74M
    Income Before Tax$53.17M$-29,942,000$-294,099,000$87.20M$71.42M$35.98M$-216,791,000$91.24M$119.65M$99.01M$208.71M$112.87M
    Income Tax Expense$53.93M$-15,140,000$-17,809,000$31.64M$18.73M$10.10M$-3,044,000$20.95M$25.39M$24.53M$19.75M$24.85M
    Net Income$-760,000$-14,802,000$-276,290,000$55.56M$52.69M$25.88M$-213,747,000$70.30M$94.26M$74.48M$188.95M$88.02M
    EBITDA$149.77M$62.92M$-193,064,000$196.34M$219.79M$182.82M$-88,288,000$208.19M$235.49M$217.17M$321.17M$224.11M
    EBIT$82.48M$-4,233,000$-271,341,000$111.18M$100.29M$62.46M$-190,392,000$120.00M$149.41M$131.81M$240.66M$145.24M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CRL

    Government Contracts

    Gov Obligations (TTM)
    $0
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    N/A
    Active Awards
    59
    New Awards (TTM)
    24
    Avg Remaining Term
    7.6 mo

    Recent Awards

    Award IDAgencyObligatedStart
    75N98025F00011Department of Health and Human ServicesNational Institutes of Health$9.67MAug 12, 2019
    75N98025F00012Department of Health and Human ServicesNational Institutes of Health$8.56MAug 12, 2019
    75N95025F00001Department of Health and Human ServicesNational Institutes of Health$7.18MSep 30, 2025
    75N98026F00002Department of Health and Human ServicesNational Institutes of Health$5.29MMar 1, 2026
    75N93025F00001Department of Health and Human ServicesNational Institutes of Health$5.24MSep 30, 2025
    75N95026F00001Department of Health and Human ServicesNational Institutes of Health$1.92MJan 20, 2026
    75N95025F00001Department of Health and Human ServicesNational Institutes of Health$1.14MSep 30, 2025
    75N98026F00001Department of Health and Human ServicesNational Institutes of Health$935908Mar 1, 2026
    75N98026F00002Department of Health and Human ServicesNational Institutes of Health$339743Jun 15, 2026
    75N98026F00001Department of Health and Human ServicesNational Institutes of Health$339743Jun 15, 2026

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Is Charles River Laboratories International (CRL) Cheap After Its Medigen Vaccine Partnership?

    Charles River Laboratories International (CRL) has drawn attention due to its recent partnership with Medigen Vaccine Biologics for next-generation vaccine work, utilizing its biologics testing and Next-Generation Sequencing platforms. While the company has seen a strong share price surge recently (64.91% in 90 days, 76.50% in 1 year), its 5-year return is down 35.88%. The most followed narrative values CRL at $313.61 per share, suggesting it is 8.1% undervalued compared to its recent close of $288.24, but investors are advised to consider risks including supply chain disruptions and its current net loss.

    Simply Wall Street•9/1/26•
    Somewhat-Bullish

    Charles River Laboratories (CRL) Earnings History & Trends

    This article provides an overview of Charles River Laboratories (CRL) earnings history and trends, detailing EPS and revenue figures against Street estimates. It highlights a 100% EPS beat rate and an average EPS surprise of +9.96%, alongside quarter-by-quarter financial data from Q1 2025 through Q2 2026. The report also includes charts illustrating CRL's EPS and revenue trends compared to market estimates and its 30-day return after each earnings report.

    24/7 Wall St.•8/31/26•
    Somewhat-Bullish

    Charles River Laboratories International Inc. stock underperforms Monday when compared to competitors

    Shares of Charles River Laboratories International Inc. (CRL) fell by 1.12% to $288.24 on Monday, marking its second consecutive day of losses. This underperformance occurred during a generally dismal trading session, with the S&P 500 Index and Dow Jones Industrial Average also experiencing declines.

    MarketWatch•8/31/26•
    Somewhat-Bearish

    Responsive Playbooks and the CRL Inflection

    This article analyzes Charles River Laboratories International Inc. (NYSE: CRL), highlighting strong sentiment across all horizons and significant upside potential due to the absence of resistance levels above the current price. It presents three AI-generated institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide investors.

    Stock Traders Daily•8/29/26•
    Bullish

    Resilient Charles River Labs stock trades close to its 52-week high as analysts see limited upside

    Charles River Laboratories International Inc. (ISIN US1591881009) is trading near its 52-week high, with its stock price significantly outpacing the consensus analyst price target, which implies potential downside. The company's stock has seen a 48.8% increase since January 1, 2026, leading investors to focus on upcoming earnings reports to validate its current valuation. As a key player in preclinical and clinical contract research services, Charles River Labs benefits from pharmaceutical R&D, with a strong position in advanced therapies like cell and gene therapy.

    Ad-hoc-news.de•8/28/26•
    Neutral

    Frequently Asked Questions About CRL

    Does CRL pay dividends?
    Charles River Laboratories (CRL) does not currently pay a regular dividend.
    What is CRL's P/E ratio?
    Charles River Laboratories has a price-to-earnings (P/E) ratio of 29.12.
    What is CRL's market cap?
    Charles River Laboratories (CRL) has a market capitalization of $13.76B with a current stock price of $288.27.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In